










































Estrogens and glucocorticoids in mammary adipose tissue:
Relationships with body mass index and breast cancer features
Citation for published version:
Laforest, S, Pelletier, M, Denver, N, Poirier, B, Nguyen, S, Walker, BR, Durocher, F, Homer, NZM, Diorio, C,
Andrew, R & Tchernof, A 2019, 'Estrogens and glucocorticoids in mammary adipose tissue: Relationships
with body mass index and breast cancer features', Journal of Clinical Endocrinology & Metabolism.
https://doi.org/10.1210/clinem/dgz268
Digital Object Identifier (DOI):
10.1210/clinem/dgz268
Link:




Journal of Clinical Endocrinology & Metabolism
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 27. Jan. 2020
Laforest et al. 2019, page 1 
Title: Estrogens and glucocorticoids in mammary adipose tissue: Relationships with body 1 
mass index and breast cancer features 2 
Authors: Sofia Laforest1,2, Mélissa Pelletier1,2, Nina Denver3,4, Brigitte Poirier5,6, 3 
Sébastien Nguyen5, Brian R Walker7,8, Francine Durocher9, Natalie ZM Homer3,7, Caroline 4 
Diorio6,10, Ruth Andrew3,7 and André Tchernof1,2 5 
Author affiliations: 1CHU de Québec-Université Laval Research Center (Endocrinology 6 
and Nephrology division), School of Nutrition, Faculty of Agriculture and Food Sciences, 7 
Université Laval, Québec, Canada; 2Quebec Heart and Lung Institute, Québec, Canada; 8 
3Mass Spectrometry Core, Edinburgh Clinical Research Facility, Queen’s Medical 9 
Research Institute, Edinburgh, United Kingdom; 4Institute of Cardiovascular and Medical 10 
Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, 11 
University Avenue, Glasgow, United Kingdom; 5CHU de Québec-Université Laval 12 
Research Center (Oncology division), Université Laval Cancer Research Center and 13 
Department of Surgery, Faculty of Medicine, Université Laval, Québec, Canada; 6Centre 14 
des maladies du sein Deschênes-Fabia, Hôpital Saint-Sacrement, Québec, Canada; 15 
7University/BHF Centre for Cardiovascular Science, Queen’s Medical Research Institute, 16 
University of Edinburgh, 47, Little France Crescent, Edinburgh, EH16 4TJ, UK; 8Institute 17 
of Genetic Medicine, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK; 9CHU 18 
de Québec-Université Laval Research Center (Oncology division), Université Laval 19 
Cancer Research Center and Department of Molecular Medicine, Faculty of Medicine, 20 
Université Laval, Québec, Canada; 10CHU de Québec-Université Laval Research Center 21 
(Oncology division), Université Laval Cancer Research Center and Department of Social 22 
and Preventive Medicine, Faculty of Medicine, Université Laval, Québec, Canada. 23 
Laforest et al. 2019, page 2 
Short Title: Steroid hormones in breast adipose tissue 24 
Keywords: estradiol, estrone, cortisol, cortisone, breast cancer, adiposity 25 
Word count: 5275 26 
Address all correspondence and requests for reprints to: André Tchernof, PhD, Quebec 27 
Heart and Lung Institute, 2725 Chemin Ste-Foy, Y4212, Québec, QC, Canada G1V 4G5, 28 
Tel: 1-418-656-8711, E-mail: andre.tchernof@criucpq.ulaval.ca. 29 
Disclosure summary: AT is the recipient of research grant support from Johnson & 30 
Johnson Medical Companies, Medtronic and Pzifer for studies unrelated to this publication. 31 
The authors have nothing to disclose. 32 
This work was supported by an inter-center grant from the CMDO to AT, CD and FD. SL 33 
is the recipient of PhD scholarships from Fonds de recherche du Québec-santé (FRQS) 34 
and the Canadian Institutes of Health Research (CIHR). SL’s internship in RA’s lab was 35 
made possible thanks to the support of the Institute of Nutrition and Functional Foods and 36 
the scholarship from the International internship program of the Fonds de recherche Nature 37 
et Technologies du Québec (FRQNT) as well as a Michael Smith Foreign Study 38 
Supplement travel scholarship. CD holds an Investigator Awards (Senior) from the FRQS. 39 
RA is funded by the Wellcome Trust. BRW is a Wellcome Trust Senior Investigator. 40 
  41 
Laforest et al. 2019, page 3 
ABSTRACT 42 
Context: Adipose tissue is an important site for extragonadal steroid hormone biosynthesis 43 
through the expression and activity of P450 aromatase, 11β-HSD1 and 17β-HSDs. The 44 
contribution of steroid hormones produced by adjacent adipose tissue for the progression 45 
and survival of breast tumors is unknown. 46 
Objective: To quantify estrogens (estradiol, estrone) and glucocorticoids (cortisol, 47 
cortisone) in breast adipose tissue from both healthy and diseased women and their 48 
relationships with adiposity indices and breast cancer prognostic markers. 49 
Design and setting: Breast adipose tissue was collected at time of surgery. 50 
Patients: Pre- and post-menopausal women undergoing partial mastectomy for treatment 51 
of breast cancer (n=17) or reduction mammoplasty (n=6) were studied. 52 
Interventions: Estrogen and glucocorticoid relative amounts were determined by liquid 53 
chromatography-tandem mass spectrometry. 54 
Results: The targeted steroids were reliably detected and quantified in mammary adipose 55 
tissues. Women with ER+/PR+ tumor had higher estradiol levels than women with ER-56 
/PR- tumor (P < 0.05). Ratio of estradiol-to-estrone was higher in lean women compared 57 
to women with a BMI ≥ 25 kg/m2 (P < 0.05). Mixed-model analyses showed that estradiol, 58 
cortisone and cortisol were negatively associated with tumor size (P < 0.05). Relationships 59 
between glucocorticoids and tumor size remained significant after adjustment for BMI. 60 
The cortisol-to-cortisone ratio was negatively associated with tumor stage (P < 0.05) 61 
independently of BMI. 62 
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Conclusions: We reliably quantified estrogens and glucocorticoids in breast adipose tissue 63 
from healthy women and women suffering from breast cancer. Our findings suggest that 64 
smaller breast tumors are associated with higher levels of estradiol and cortisol in adipose 65 
tissue.  66 
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PRÉCIS 67 
Estrogens and glucocorticoids were measured by LC-MS/MS in breast fat tissue from 68 
women with or without breast cancer. Tumor size was negatively associated with estradiol 69 
and glucocorticoid levels. 70 
  71 
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INTRODUCTION 72 
Being overweight or obese is a well-known risk factor for postmenopausal breast cancer 73 
1,2. Obesity is also linked to a poorer prognosis in women with breast cancer regardless of 74 
their menopausal status 1,3,4. Women with obesity have more aggressive tumors, higher 75 
mortality rates, incidence of metastases and increased risk of recurrence 1,5-8. Central 76 
obesity, as measured by waist circumference (WC), is an emerging risk factor for both pre- 77 
and postmenopausal breast cancer 9. Furthermore, the efficacy of chemotherapy, 78 
radiotherapy, surgery and endocrine therapy is reduced in women with obesity and possibly 79 
more so with increased visceral fat accumulation 10-14. The mechanisms underlying higher 80 
risk and reduced treatment efficacy are not fully understood. Altered secretion of 81 
adipokines, growth factors and steroids by dysfunctional mammary adipose tissue may 82 
contribute to a pro-inflammatory, growth-promoting microenvironment for cancer cells 15. 83 
Recent evidence from human studies has shown that local breast adipose tissue does 84 
present an altered biological profile, as described above, concomitant with body mass index 85 
(BMI) increases 16-21. Reports from Iyengar and collaborators have showed that mean 86 
adipocyte cell size from breast adipose tissue was positively associated with BMI, 87 
increased aromatase expression and inflammatory markers such as crown-like structures 88 
and was also related to menopausal status 19,20. 89 
Expression and activity of several steroidogenic enzymes present in adipose tissue have 90 
been linked to increased adiposity 22. For example, higher rates of androgen-to-estrogen 91 
conversion through aromatization in adipose tissue 22 have been proposed as a mechanism 92 
for the obesity-related increase in breast cancer risk. Findings from our group suggest that 93 
known estrogenic 17β-HSD (type 1, 7 and 12)-mediated conversion of estrone (E1) to 94 
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estradiol (E2) is five times higher in differentiated adipocytes than in preadipocytes 23. 95 
Increased mean adipocyte size is associated with higher expression level and activity of 96 
11β-HSD type 1 which locally converts cortisone to active cortisol through oxoreductase 97 
activity 24,25. 98 
Despite their well-known anti-inflammatory effects, glucocorticoids (GC) could contribute 99 
to breast cancer initiation, progression and survival via the activation of the glucocorticoid 100 
receptor (GR) or by increasing aromatase expression via the GC response element (GRE) 101 
on exon I.4 of the CYP19A1 gene 26. Moreover, 11β-HSD1 expression increases with 102 
estrogen receptor β (ERβ) activation 27. In a rodent model of breast cancer, increased GC 103 
levels nurtured the transition from DCIS (ductal carcinoma in situ) to IDC (invasive ductal 104 
carcinoma) while administration of RU-486 was able to partially block this effect, i.e. 105 
prevent breast cancer progression to IDC 28. Considering the slow turnover of GC in 106 
adipose tissue 29, there is biological plausibility for autocrine and paracrine effects of active 107 
GC, such as cortisol, in the tumoral microenvironment. 108 
Hence, steroid dynamics in breast adipose tissue and cancer appear to be involve more than 109 
overexpression and increased activity of aromatase. We currently have very little 110 
information about the relative importance of adipose tissue dysfunction markers such as 111 
altered steroid conversion to tumor progression and aggressiveness or patient prognosis. 112 
Moreover, considering the complexity of potential enzymatic hormone conversion in 113 
adipose tissues, direct measurement of active hormone levels and their precursors has 114 
become highly relevant. 115 
Liquid-chromatography followed by tandem mass spectrometry (LC-MS/MS) is 116 
recognized as the gold standard to quantify endogenous steroids in plasma, however, tissue 117 
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steroids are harder to measure than those in plasma due to the complexity of the matrix and 118 
the need to homogenize uniformly. Measurements are confounded by the low abundance 119 
and the poor ionisation profile of steroids as well as the higher concentrations of lipids in 120 
adipose tissue than in plasma, which result in higher susceptibility of so-called matrix 121 
effects. We aimed to characterize the relationship of locally-produced cortisol and E2 as 122 
well as inactive steroid cortisone and main E2 precursor E1, with adiposity and prognostic 123 
markers in a sample of women with or without breast cancer. We hypothesize that 124 
independently of menopausal status: i) E2 and cortisol breast adipose tissue levels as well 125 
as the ratio E2/E1 and cortisol on cortisone are increased with adiposity; ii) worst clinical 126 
breast cancer features, such as tumor stage, size and grade are associated with lower 127 
adipose tissue steroid levels; and iii) estrogen relative amounts are increased in women 128 
with ER+/PR+ tumors. We also investigated if these relationships were independent of 129 
total adiposity i.e. reflecting the micro-environment or a characteristic of the adiposity 130 
state. 131 
  132 
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METHODS 133 
Study sample and data collection 134 
The study protocol was approved by the Research Ethics Committees of Laval University 135 
Medical Center (DR-002-136). All patients signed a written, informed consent prior to 136 
surgery. Breast adipose tissue was obtained from women undergoing partial or total 137 
mastectomy for treatment of breast cancer (n = 17) or reduction mammoplasty (n = 6). 138 
Fresh tissue specimens were acquired from residual resected breast tissues that were not 139 
required for clinical diagnosis at least 1 cm away from the tumor margins. Information on 140 
clinicopathologic and anthropometric factors was collected from in-person interviews, 141 
phone-call interviews and medical records. 142 
Laboratory methods 143 
Cell sizing 144 
Breast adipocyte size was measured as previously described 30,31 in formalin-fixed adipose 145 
tissue. Briefly, 250 breast adipocytes from 10 randomly chosen areas at × 40 magnification 146 
using Calopix software (Tribvn) were measured for each subject, in a blinded fashion. 147 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 148 
Standards and solvents 149 
E1 and E2 were obtained from Steraloids, Inc (Newport, USA). Cortisone, cortisol, formic 150 
acid (FA; ≥ 98%), iodomethane (≥ 99%), were from Sigma-Aldrich, Inc. (Dorset, UK). 1-151 
(2,4-dinitro-5-fluorophenyl)-4-methylpiperazine (PPZ) was obtained from TCI chemicals 152 
(Chuo-ku, Tokyo, Japan). HPLC grade glass distilled solvents (acetone; ethyl acetate, 153 
EtOAc; water) were from Fisher Scientific UK Limited (Leicestershire, UK). Analytical 154 
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reagent (AR) grade ethanol (EtOH) and HPLC grade glass distilled solvents (acetonitrile; 155 
methanol, MeOH) and LCMS grade (acetonitrile; formic acid, FA; water) solvents were 156 
from VWR (England, UK). 157 
Instrumentation 158 
Cortisone, cortisol, E1 and E2 were measured by LC-MS/MS, using a UHPLC Shimadzu 159 
Nexera X2 system (UK) coupled to a Sciex QTRAP® 6500+ (SCIEX, Warrington, UK) 160 
equipped with an electrospray ionization interface (ESI). Mass spectrometry conditions 161 
were previously described in conjunction with ion spray voltage (5500 V) and source 162 
temperature (500°C) 32.  163 
Sample preparation 164 
Following enrichment of frozen adipose tissue samples (~200 mg) with three internal 165 
standards (IS), 9,11,12,12-[2H4]-cortisol (D4-F 5 ng; Cambridge Isotopes Laboratory, 166 
England, UK), 2,3,4-[13C3]-17β-estradiol and 2,3,4-[13C3]-estrone (13C3E2, 13C3E1 167 
respectively; 5 ng; Sigma-Aldrich, Inc (St. Louis, USA)), analytes were extracted as 168 
described below. 169 
Briefly, frozen adipose tissue samples were homogenized (Model Pro 200, ProScientific, 170 
Inc, Monroe, CT, USA) in EtOH:EtOAc (1 mL; 1:1) and immediately frozen on dry ice 171 
and stored at -80°C overnight. The following morning, samples were thawed on wet ice 172 
and sonicated (8 x 15 second bursts with 1-minute gaps; Ultrasonic cleaner, Branson 173 
Ultrasonic Inc, Danbury, CT, USA). Samples were subjected to centrifugation (3200 g, 174 
45 minutes, 4°C; Heraeus Megafuge 16R, ThermoFisher Scientific, Germany). The 175 
supernatant was transferred into a new glass tube and dried down under oxygen-free 176 
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nitrogen (OFN; 60°C). Samples were resuspended in aqueous MeOH (30% v/v, 5 mL). 177 
Solid-phase extraction was carried out after conditioning C18 Sep-Pak columns (12cc, 2g; 178 
Waters, Wilmslow, UK; MeOH (2 x 10 mL), followed by H2O (2 x 10 mL)). The adipose 179 
extract was loaded, and the column was washed with H2O (10 mL) followed by aqueous 180 
MeOH (5%, 10 mL). Steroids were eluted with MeOH:CH3CN (1:1, 10 mL). The eluent 181 
was dried down under OFN at 60°C prior to derivatization of estrogens. Generation of 1-182 
(2,4-dinitrophenyl)-4,4-dimethylpiperazinium (MPPZ) derivatives of E1 and E2 has 183 
already been described 32-34. Derivatization was carried out by incubating (1h, 60°C) with 184 
(CH3)2CO (70 µL), NaHCO3 (10 µL, 1M, Sigma-Aldrich, Inc (St-Louis, USA)) and PPZ 185 
(10 µL, 1 mg/mL, dissolved in (CH3)2CO) followed by addition of CH3I; (100 µL) and 186 
further incubation (2h, 40°C) as previously described 33,34. Samples were dissolved in 187 
H2O:CH3CN (70 µL; 70:30) and transferred to LC vials. 188 
Liquid chromatography parameters 189 
Following injection (30 µL), analytes were separated on an ACE 2 Excel C18-PFP 190 
(150 × 2.1 mm, 2 μm; HiChrom, Reading, England, 40°C) column. The elution process 191 
started with mobile phase compositions of 90:10 H2O with 0.1% FA (solution A) and 192 
CH3CN with 0.1% FA (solution B) which was maintained for 1 minute. This was followed 193 
by an 11-minute linear gradient to 50% solution B, which was maintained for 2 minutes, 194 
before returning to 10% solution B at 15 minutes and maintained for 3 minutes, all at a 195 
constant flow rate of 0.5 mL/min. 196 
 Linearity and lower limit of quantitation (LLOQ) 197 
Blank samples and aliquots containing estrogens (5, 7.5, 10, 15, 25, 50, 100, 200, 500, 198 
1000 pg/sample), GC (50, 75, 100, 150, 250, 500, 1000, 2000, 5000, 10000 pg/sample) and 199 
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IS (500 pg) were analysed by LC–MS/MS. Calibration curves were plotted as the peak area 200 
ratio (standard/IS) versus amount of analytes (GC or estrogens). Calibration lines of best 201 
fit were acceptable if the regression coefficient, r, was > 0.98. Weightings of 1/x were used 202 
for all four steroids. LLOQs were 50 pg, 15 pg, 100 pg and 75 pg for E2, E1, cortisol and 203 
cortisone, respectively. Values below the confirmed LLOQ were calculated as LLOQ 204 
divided by 3 i.e. the lowest acceptable signal-to-noise ratio. The values were then converted 205 
to pmol/kg according to the weight of the corresponding adipose tissue sample. This 206 
transformation was performed to avoid null values to calculate steroid ratios as described 207 
below. 208 
Calculated ratios 209 
All steroid amounts were converted into pmol/kg. Those values were then used to calculate 210 
product and substrate ratios, as described below. The ratio of cortisol:cortisone was used 211 
as a marker of 11β-HSD1 enzyme activity. The ratio of E2:E1 was used as a marker of 212 
estrogenic 17β-HSD enzyme activity. 213 
Gene expression 214 
Tissues were homogenized in Qiazol buffer (Qiagen, Germantown, MD, USA) and total 215 
RNA was extracted using the RNeasy mini kit on-column DNase (Qiagen, Hilden, DE) 216 
treatment following the manufacturer’s instructions. First-strand cDNA synthesis was 217 
accomplished using 1 ug of RNA in a reaction containing 200 U of Superscript IV Rnase 218 
H-RT (Invitrogen Life Technologies, Burlington, ON, CA). cDNA corresponding to 20 ng 219 
of total RNA was used to perform fluorescent-based Realtime PCR quantification using 220 
the LightCycler 480 (Roche Diagnostics, Mannheim, DE). Reagent LightCycler 480 221 
SYBRGreen I Master (Roche Diagnostics, Indianapolis, IN, USA) was used as described 222 
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by the manufacturer. The conditions for PCR reactions were: 45 cycles, denaturation at 223 
95°C for 10 sec, annealing at 58-60°C for 10 sec, elongation at 72°C for 14 sec and then 224 
72°C for 5 sec (reading). Oligoprimer pairs were designed by GeneTool 2.0 software 225 
(Biotools Inc, Edmonton, AB, CA) and their specificity was verified by blast in the 226 
GenBank database. The synthesis was performed by IDT (Integrated DNA Technology, 227 
Coralville, IA, USA) (Table 1). Normalization was performed using the following 228 
reference genes ATP synthase O subunit (ATP5O), hypoxanthine guanine phosphoribosyl 229 
transferase 1 (HPRT1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 230 
Quantitative Real-Time PCR measurements were performed by the CHU de Québec 231 
Research Center (CHU) Gene Expression Platform, Quebec, Canada and were compliant 232 
with MIQE guidelines. 233 
Statistical analyses 234 
Differences in breast adipocyte diameter between women with breast cancer (cases) and 235 
women without breast cancer (controls) or according to menopausal status were assessed 236 
by Student’s t-test. Cell size frequency distribution differences between case and control 237 
subjects or according to menopausal status were assessed by the Kolmogorov–Smirnov 238 
(KS) test. Women were subdivided in categories of BMI [lean (< 25 kg/m2) or overweight 239 
and obese (≥ 25 kg/m2)] or according to their estrogen and progesterone receptor (ER/PR) 240 
status. Hormone levels or ratios between those subgroups were assessed by Student’s t-241 
test. Satterthwaite approximation was used when variances were deemed unequal 242 
according to a conservative Folded F statistic (P < 0.10). Exact p-values computed using 243 
non-parametric Wilcoxon tests showed similar results. Women were subdivided according 244 
to their respective tumor size, according to tertiles of the distribution. A mixed-model was 245 
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performed to evaluate the relationship between hormone levels and tumor size (in tertiles 246 
or continuous; as determined by the best AIC fit for the model), grade (categorical) and 247 
stage (categorical). A repeated statement was incorporated into the model to account for 248 
the non-constant variance among the residuals i.e. specifying a variance component 249 
covariance structure in the model. Non-normally distributed variables were log-250 
transformed to achieve normality and linearity. Models were further adjusted for BMI (as 251 
a continuous variable) to account for total adiposity. Adjustments for menopausal status 252 
and current use of hormonal derivatives (as combined indicator variables) were also 253 
performed as they are identified as confounders in the breast cancer literature. Spearman 254 
correlation coefficients were computed to assess the relationship between steroid relative 255 
amount, prognostic factors and relative expression of genes. P-values < 0.05 were 256 
considered significant. All statistical analyses were performed with SAS software (SAS 257 
Institute, Cary, NC, USA). 258 
  259 
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RESULTS 260 
Table 2 shows the characteristics of the study sample. Women were overweight with a 261 
median BMI of 25.6 kg/m2 and a median age of 55 years. Postmenopausal status was 262 
equally balanced across case and control women. Table 3 presents the clinicopathological 263 
features of pre-menopausal and post-menopausal breast cancer patients. Most women 264 
presented with a unilateral breast lesion. Breast tumors were mainly of ductal histology 265 
(82%). Only one woman presented a HER2+ tumor and 13 women had an ER+/PR+ tumor. 266 
Half of the women had stage 2 breast cancer as classified by TNM score 35. 267 
Women with or without breast cancer were comparable for primary clinical characteristics, 268 
except for mean fat cell size which was 13.3 µm higher in the control women (t-test, 269 
P = 0.0072). This difference was also shown by the adipocyte size distribution curve 270 
comparison (KS, P = 0.0041) (Figure 1A). Postmenopausal women had a 9.7 µm higher 271 
mean adipocyte size compared to premenopausal women as well as a right-shifted 272 
adipocyte size distribution, however this difference was not statistically significant (Figure 273 
1B). The distribution remained similar when considering only cancer cases (Figure 1C). 274 
 Quantification of steroids 275 
Table 4 shows adipose tissue steroid relative amounts and calculated ratios. E1 and cortisol 276 
relative amounts were quantified in each of the 23 samples of mammary adipose tissue. E2 277 
level was below the limit of quantification for 2 samples. Cortisone level was below the 278 
limit of quantification for 5 samples, 4 of which were obtained from control women. 279 
11β-HSD1 mRNA abundance was positively correlated with the cortisol:cortisone ratio 280 
(r = 0.4929; P = 0.0198) and negatively associated with the cortisone relative amount 281 
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(r = - 0.4850; P = 0.0221). In women with ER+/PR+ tumor, 17β-HSD12 transcript amount 282 
(r = 0.5804; P = 0.0479) was correlated with E1 relative amount in breast adipose tissue. 283 
17β-HSD12, 17β-HSD7 or CYP19A1 were not correlated with E2 relative amount. 284 
Women with cancer had higher expression level of 17β-HSD12 mRNA compared to 285 
controls (P = 0.0231). E2 relative amount was positively associated with ERβ mRNA 286 
expression (r = 0.6083, P = 0.0358), but not ERα mRNA expression in women with 287 
ER+/PR+ tumor. In women with breast cancer, abundance of CYP19A1 transcript was 288 
positively correlated with 11β-HSD1 mRNA expression (r = 0.5353, P = 0.0326). 289 
 Adiposity 290 
The ratio of E2 to E1 was higher in lean women compared to women with a BMI ≥ 25 291 
kg/m2 (P = 0.0335) (Figure 2A) (postmenopausal, n=15, P=0.0072; premenopausal, n=8, 292 
P=NS) in the entire cohort, even if CYP19A1 expression was higher in women with a 293 
BMI ≥ 25 kg/m2  (p<0.05). This difference remained significant when considering only 294 
cancer cases (P = 0.0393, n = 17), or only ER+/PR+ patients (P = 0.0436, n = 13). The 295 
difference, although the same magnitude as above, was no longer statistically significant 296 
when considering ER+/PR+ patients with invasive carcinoma (stage ≥ 1) (P = 0.0900, 297 
n = 11). E2 levels were higher in lean women than in overweight and obese women in 298 
cancer cases (P = 0.0494) (Figure 2B) (postmenopausal, n=11, P=0.0325; premenopausal, 299 
n=6, P=NS). cancer cases (P = 0.0494) (Figure 2B). There was no difference in levels of 300 
cortisol and cortisone between lean and overweight/obese women (data not shown).  301 
 Breast cancer clinical features 302 
Adipose tissue E2 level (log-transformed) was inversely associated with tumor size 303 
(categorical variable) (Figure 3A) (P = 0.0281, n = 17) (postmenopausal, n=11, P=0.0283; 304 
Laforest et al. 2019, page 17 
premenopausal, no convergence), but this relationship did not reach statistical significance 305 
when tumor size was treated as a continuous variable (β = - 0.0199, P = 0.1089, n = 17). 306 
Further adjustment for menopausal status and use of hormonal derivatives did not alter the 307 
results (P = 0.0488, n = 17) whereas the relationship was no longer significant after 308 
adjusting for BMI (P = 0.1569, n = 17) or when considering only patients with invasive 309 
carcinoma (stage ≥ 1) (P = 0.1157, n = 14). Including only women with ductal carcinoma 310 
generated similar effect size. Although the adjusted models were no longer significant, the 311 
non-adjusted model remained significant (data not shown). CYP19A1 mRNA expression 312 
level was positively correlated with tumor size (r = 0.4875, P < 0.05), whereas expression 313 
of ERα mRNA was negatively associated with this variable (r = - 0.5435, P = 0.0296). 314 
There was no relationship between adipose tissue estrogen levels and tumor stage or tumor 315 
grade in our sample. 316 
The ratio of cortisol to cortisone was lower in women with cancer compared to control 317 
women (P < 0.0001). This difference was driven by higher cortisone levels and not lower 318 
cortisol levels. In fact, cortisone levels were higher in cancer patients than in control 319 
patients (P = 0.0055). These differences remained when combining controls with women 320 
with ER-/PR- breast cancer, who shared similar characteristics (Table 5), and comparing 321 
them to women with ER+/PR+ tumor (P = 0.0097 and P = 0.0171, respectively) (data not 322 
shown). 323 
No difference was detected between control women and cancer-positive women with 324 
respect to cortisol (data not shown). Both log-transformed cortisol and cortisone levels 325 
were inversely associated with tumor size [(β = - 0.01873, P = 0.0007) and (β = - 0.05048, 326 
P < 0.0001)] independent of BMI, menopausal status and current use of hormonal 327 
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derivatives [(β = - 0.02135, P = 0.0027) and (β = - 0.03636, P < 0.0001)] (Figure 3BC) 328 
when tumor size was treated as a continuous variable. When we stratified according to 329 
menopausal status, the mixed-models remained significant for postmenopausal women 330 
(n=11) (Figure 3BC; P=0.0055, P<0.0001) but did not converge for premenopausal 331 
women (n=6). Those relationships were still significant when including only patients with 332 
invasive tumors [Cortisol: (β = - 0.02376, P = 0.0078); (βadj = - 0.02977, P = 0.0079) and 333 
Cortisone (β = - 0.03328, P < 0.0001); (βadj = - 0.03650, P < 0.0001)]. Contrary to 334 
estradiol, cortisone and cortisol were not associated with tumor size (all TNM stages 335 
included or with only invasive tumors) (P = 0.0904 and P = 0.1894). Tumor stage was 336 
negatively associated with cortisol/cortisone ratio independent of BMI (β2 = - 1.8720, 337 
β3 = - 1.8316; P = 0.0410) (Figure 3D) (postmenopausal, n=11, P=0.0660; 338 
premenopausal, n=6, P=0.3096). In sensitivity analyses, including only women presenting 339 
a ductal carcinoma histology phenotype, the models generate similar results (data not 340 
shown). There was no relationship between adipose tissue glucocorticoid levels and tumor 341 
grade in our sample. 342 
Higher levels of E2 and E1 were detected in the adipose tissue of women with ER+/PR+ 343 
tumor compared to women with ER-/PR- tumor (P = 0.0163 and P = 0.0134, respectively) 344 
(Figure 3E) (postmenopausal, n=11, P=0.1077 and P=0.4324, respectively; 345 
premenopausal, no convergence). 346 
  347 
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DISCUSSION 348 
To our knowledge, this is the first study to report a LC-MS/MS quantification method 349 
combining analysis of cortisone, cortisol, E1 and E2 extracted from breast adipose tissue 350 
from both healthy women and women with breast cancer. Several lines of evidence showed 351 
that adipose tissue might play an active role in tumor initiation and progression 18,36,37. As 352 
such, the notion of an active cross-talk between adipose and tumor cells has been put 353 
forward in the literature 15,38,39. Yet, the contribution of adipose tissue to the steroid 354 
hormone relative amounts and their possible actions remain to be fully elucidated. Most of 355 
the steroidogenic pathways have been studied directly in breast tumors or in vitro. Reports 356 
of endogenous steroid hormones in breast adipose tissue are mostly comprised of analyses 357 
of estrogens (E1 and E2) and their corresponding fatty acyl-esters as well as androgen 358 
precursors, namely androstenedione and testosterone 40-43. Of note, a recent study 359 
characterised more than 20 steroids, including androgens, progestogens and estrogens in 360 
breast adipose tissue by gas chromatography-tandem mass spectrometry (GC-MS/MS) 44. 361 
A limitation of that study is the lack of data regarding normal breast adipose tissue from 362 
healthy controls. In vitro uptake of E1, E2 and cortisol from culture media by female 363 
abdominal adipose tissue explants was reported as more than two-fold lower compared to 364 
progesterone and testosterone, highlighting the possible contribution of steroid conversion 365 
in adipose tissue as a source of estrogens and GC for the tumor 45. 366 
Quantification of steroids 367 
We have been able to quantify these four steroids in most of our breast adipose samples. 368 
Interestingly, we found similar ranges in relative amounts for estrogens as those reported 369 
by Honma and collaborators in breast cancer tissue, using LC-MS/MS 46. These findings 370 
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suggest that breast adipose tissue is a potent source of sex hormones for the tumor. One of 371 
the strengths of our study is the use of stable isotope dilution LC-MS/MS instead of the 372 
historically used ELISAs (enzyme-linked immunosorbent assay). ELISAs for steroid 373 
measurements have several drawbacks such as nonspecific antibody interactions, 374 
inconsistent reproducibility and inadequate sensitivity 47. Moreover, they usually require 375 
separate assays for each compound of interest, demanding a large quantity of tissue. Using 376 
three stable isotope labelled standards in our protocol allowed us to normalize for loss of 377 
analytes during the extraction process. 378 
Contrary to our hypothesis, our data, reported as pmol/kg of whole adipose tissue, showed 379 
a decrease in the ratio of E2/E1 and a decrease of E2 with increasing adiposity, as assessed 380 
with the BMI, suggesting little impact of aromatase conversion per mass unit in adipose 381 
tissue. This can also be explained by the higher affinity of androstenedione as a substrate 382 
for aromatase compared to testosterone, as previously reported 48. Marchand et al. reported 383 
that higher circulating E2 level is directly associated with increased fat mass 49. Simpson 384 
et al. reported that increased aromatization in obesity was due to a higher number of cells 385 
and not to higher conversion activity per adipose tissue mass unit 50. Our results are also 386 
consistent with another study where the authors found a positive correlation between E1/E2 387 
ratio from visceral fat and BMI in postmenopausal women 51. Contrary to Savolainen-388 
Peltonen, we found that 17β-HSD type 12 mRNA expression is higher in adipose tissue 389 
from cancer patients compared to controls 43. We cannot exclude that the lower levels of 390 
E2 observed in adipose tissue of overweight and obese women are due to increased uptake 391 
by the tumor cells as previously proposed by Savolainen-Peltonen 43. However, we 392 
observed this difference in our entire sample and with all women with cancer, including 393 
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those with ER- status. Effect size were not modified when stratification by ER+/PR+ was 394 
performed. 395 
We were unable to find a significant association between BMI and cortisol levels in breast 396 
adipose tissue. We acknowledged that this may be due to our limited sample size. However, 397 
we found lower and non-quantifiable cortisone levels in breast adipose tissue of our control 398 
women (4 out of six). Our group of control women had higher mean adipocyte size than 399 
our women with cancer. This is not surprising, as our control women tended to have higher 400 
BMI than the women with cancer, although not statistically significant probably because 401 
of our small sample. The adipocyte size difference reported between pre- and post-402 
menopausal women is similar to the findings of Iyengar and collaborators19. The lower 403 
levels of cortisone could be partially explained by a higher activation rate of cortisol or a 404 
lower inactivation of cortisol to cortisone by 11β-HSD1, because our gene expression 405 
results suggest that 11β-HSD1 expression is positively associated with the 406 
cortisol:cortisone ratio and negatively associated with the cortisone relative amount These 407 
results are consistent with previous findings from our team which showed that 11β-HSD1 408 
activity and expression is positively associated with adipocyte size, at least in the 409 
abdominal subcutaneous and omental depots 24,25. A previous study with obese subjects 410 
undergoing bariatric surgery has indeed found lower levels of cortisone in adipose tissue 411 
of obese subjects before weight loss and when compared to control with no difference in 412 
adipose tissue cortisol levels among those groups 52. No difference in tissue relative amount 413 
of cortisol could be explained by concomitant higher clearance by 5α-reductase, also 414 
increased in obesity 53. However, our data showed no decrease of cortisone with higher 415 
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BMI which suggests a different catabolism of cortisol and cortisone in women with breast 416 
cancer. 417 
Some steroids were previously proposed to be increased in adipose tissue during obesity 418 
such as cortisol, which could also act as an immune suppressor in breast tissue. As reported 419 
by Cirillo et al., many different tumor types produce active cortisol which inhibits tumor-420 
specific CD8+ T proliferation in vitro 54. Infiltration of CD8+ cells was linked to improved 421 
cancer-specific survival by Mohammed and collaborators 55. However, breast cancer was 422 
one of the types of cancer not showing any difference between 11β-HSD1/2 expression 423 
between cancer and matched normal epithelial tissues, which suggest a paracrine, possibly 424 
by adjacent adipose tissue instead of an autocrine effect by cortisol 54. In the same order of 425 
ideas, immunohistochemistry of 11β-HSD1 showed a presence of the enzyme in 64% of 426 
breast tumors and 97% of matched adjacent tissue 56 and GR protein level was higher in 427 
breast tumor vs normal epithelial tissue 57. Increases in GC, particularly cortisol, can induce 428 
aromatase expression via the GRE on exon I.4 26. On the other hand, cortisol via binding 429 
to GR is an activator of the estrogen sulfotransferase, which inactivates estrogens by adding 430 
a sulfate group and limiting its binding to ER 58. 431 
We did observe higher cortisone levels in adipose tissue from women with cancer with no 432 
change in cortisol. As per our initial hypothesis, we did observe a decrease of estradiol, 433 
cortisol and cortisone adipose tissue levels according to tumor size and a decrease of 434 
cortisol/cortisone ratio with increasing tumor stage. As stated previously, the decrease of 435 
estradiol, but not estrone with tumor size could represent an increased uptake by the tumor 436 
cells 42. The higher cortisol/cortisone ratio between cancer patients in comparison to control 437 
women and the further decrease of this ratio with tumor stage point to a dual effect of 438 
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glucocorticoids in breast cancer related to stage of the disease. Increases in 439 
cortisol/cortisone ratio at the lower stages could increase estrogen production via activation 440 
of aromatase, but at a later stage, decreases in cortisol/cortisone could be explained by a 441 
negative feedback loop through increased estrogen production by the tumor and a 442 
concomitant lower expression of 11β-HSD1. However, we were unable to demonstrate a 443 
relationship between cortisol/cortisone ratio with E2/E1 ratio or E2 and E1 in our sample, 444 
contrary to previous results in visceral adipose tissue, but similar to results in subcutaneous 445 
tissue 51. 446 
Despite our relatively low number of patients in both groups, we found that median E2 447 
adipose tissue level was higher in women ER+/PR+ than ER-/PR-. Hennig et al. reported 448 
higher adipose tissue E2, androstenedione and androsterone levels in women with ER+ 449 
breast cancer compared to ER-, but no difference in E1 or any of the other androgens and 450 
progestagens 44. Falk et al. measured sex steroids by radioimmunoassay and found a 451 
significant difference only for testosterone and a trend for higher E2, E1 and 452 
androstenedione adipose tissue levels in ER+/PR+ compared to ER-/PR- samples 40. We 453 
found that E2 relative amount was associated with ERβ mRNA, but not that of ERα in 454 
women with ER+/PR+ tumor. ERβ expression is known to be increased with E2 455 
production, not ERα, either suggesting a negative feedback or no effect depending on depot 456 
origin 59. ERβ is only expressed in mature adipocytes in adipose tissue whereas ERα is 457 
present in both the stroma-vascular fraction and in mature adipocytes 60. Lower ERα 458 
expression has been linked with adipose tissue dysfunction 61. However, a relationship with 459 
adipocyte cell size and ERα expression level was not observed in our study. 460 
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Limitations of our study comprised the relatively low number of participants which is 461 
counterbalanced by the wide range of BMI and prognostic marker values of our cohort. Of 462 
note, our total sample number is in the same order of magnitude compared to previous 463 
literature on breast adipose tissue steroid measurements 40-43, representing the difficulty in 464 
obtaining those samples for research purposes. Moreover, we have included in our analysis, 465 
control samples i.e. samples from healthy women. 466 
Data on steroid concentration in breast adipose tissue from healthy control and women with 467 
cancer is scarce in the literature. Most publications investigated this relationship in 468 
postmenopausal women 40,41,43 with the exception of Hennig et al. 44, who did include 469 
premenopausal women (n=6 out of 51) in their analyses. They did not, however, separate 470 
according to menopausal status due their low number of premenopausal women. We 471 
acknowledge the potential difference in hormone metabolism between pre- and 472 
postmenopausal women. Because the main source of estrogens shifts from gonads to 473 
peripheral tissues in menopause, we adjusted for menopausal status and age in our analysis. 474 
We also performed stratification to further alleviate concerns about the influence of 475 
menopausal status, but these analyses should be interpreted with caution. It should be noted 476 
that inference in our study is limited to postmenopausal women, as our number of 477 
premenopausal women did not allow us to investigate fully their steroid concentration as a 478 
separate group. Most of our findings were still significant when including only 479 
postmenopausal women. Of note, tissue steroid concentration in our study did not vary as 480 
a function of menopause. Our cohort represents normal demographics in breast cancer, i.e. 481 
increased prevalence in older, postmenopausal women. Hence, we suggest that these 482 
findings are relevant in this context. 483 
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The use of a cross-sectional design does not allow for causal inferences and we 484 
acknowledge that there might be reverse causality as higher tumor stage and size may cause 485 
changes in steroid metabolism rather than the opposite. Another constraint is that we cannot 486 
quantify the distance from the tumor at which the adipose tissue samples were taken. 487 
However, as the defined margins were all included in paraffin blocks for 488 
clinicopathological assessment directly at the hospital, we can attest that our adipose 489 
samples were taken at least 1 cm from the tumor extremities. Hennig et al reported no 490 
difference between steroid levels between two sample locations (less than 0.5 cm and more 491 
than 5 cm), except for E2 44. Due to standard of care and acceptable limit margins in 492 
Quebec for clinicopathological assessment, it was not possible to include adipose tissue 493 
less than 0.5 cm away from the tumor in a research project. Therefore, the variation of E2 494 
due to the relative distance from the tumor was likely limited. 495 
  496 
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CONCLUSION 497 
We were able to quantify estrogens and glucocorticoids in breast adipose tissue from both 498 
healthy women and women suffering from breast cancer. There is clear indication that 499 
steroid hormone metabolism is different among those two subgroups. Moreover, relative 500 
amounts of sex steroids in adipose tissue appear to be related to BMI, especially for E2, 501 
whereas differences in glucocorticoids levels appear to be more closely related to cancer 502 
progression. As such, estradiol levels were lower in women with larger tumors 503 
independently of age and menopausal status and glucocorticoid breast adipose tissue levels 504 
were negatively associated with tumor size, independently of age, menopausal status and 505 
BMI.  506 
  507 
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FIGURE HEADINGS 741 
Figure 1: Size distribution of breast adipocytes. (A) Comparison between control and 742 
case women (t-test, P=0.0072; KS, P=0.0041; n=22). (B) Comparison between 743 
premenopausal and postmenopausal women (t-test, P=0.0510; KS, P=0.0864; n=22). (C) 744 
Comparison between premenopausal and postmenopausal women with cancer (t-test, 745 
P=0.0552; KS, P=0.0480; n=16). 746 
Figure 2: Adiposity and estrogens in breast adipose tissue. (A) Difference of the 747 
estradiol/estrone ratio according to BMI status using 25 kg/m2 as a cut-off (P=0.0335, 748 
n=23). (B) Difference of estradiol levels in women with cancer according to BMI status 749 
using 25 kg/m2 as a cut-off (P=0.0494, n=17). Data on graphs are mean. Open circles 750 
represent premenopausal women data point. 751 
Figure 3: Breast cancer clinical features and breast adipose tissue steroid levels. (A) 752 
Mixed-model regression between estradiol relative amount (log-transformed) and tertiles 753 
of tumor size adjusted for menopausal status and current intake of hormonal derivatives 754 
(β2 = - 0.9785, β3 = - 1.1197; P=0.0488). (B) Mixed-model regression between cortisol 755 
relative amount (log-transformed) and tumor size (continuous) adjusted for BMI, 756 
menopausal status and current intake of hormonal derivatives (β = - 0.02135, P=0.0027). 757 
(C) Mixed-model regression between cortisone relative amount (log-transformed) and 758 
tumor size (continuous) adjusted for BMI, menopausal status and current intake of 759 
hormonal derivatives (β = - 0.03636, P < 0.0001). (D) Mixed-model between 760 
cortisol/cortisone ratio (log-transformed) and tumor stage adjusted for BMI (β2 = - 1.8720, 761 
β3 = - 1.8316; P=0.0410). (E) Difference in estradiol and estrone levels in ER-/PR- vs 762 
ER+/PR+ women (P=0.0134 and P=0.0454). Data on graphs are mean. n=17. Open circles 763 
represent premenopausal women data point. 764 
  765 
Laforest et al. 2019, page 35 
 766 
LIST OF ABBREVIATIONS 767 






17β-HSD: 17β-hydroxysteroid dehydrogenase  771 
AR: Analytical reagent 772 
BMI: Body mass index 773 
CD8+ T: Cytotoxic T cell 774 
CI: Confidence interval 775 
D4F: 9,11,12,12 [
2H4]-cortisol 776 
DCIS: Ductal carcinoma in situ 777 
E1: Estrone 778 
E2: Estradiol 779 
ELISA: Enzyme-linked immunosorbent assay 780 
ER: Estrogen receptor 781 
ERβ: Estrogen receptor beta 782 
ESI: Electrospray ionization  783 
EtOAc: Ethyl acetate 784 
EtOH: Ethanol 785 
FA: Formic acid 786 
GC: Glucocorticoids 787 
GC-MS/MS: Gas chromatography-tandem mass spectrometry 788 
GR: Glucocorticoid receptor 789 
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GRE: Glucocorticoid response element 790 
HER2: Human epidermal growth factor receptor 2 791 
HPLC: High-performance liquid chromatography 792 
HRT: Hormonal replacement therapy 793 
IDC: Invasive ductal carcinoma  794 
IQR: Interquartile range 795 
IS: Internal standards 796 
KS: Kolmogorov-Smirnov 797 
LC-MS/MS: Liquid chromatography-tandem mass spectrometry 798 
LLOQ: Lower limit of quantitation 799 
MeOH: Methanol 800 
MPPZ: 1-(2,4-dinitrophenyl)-4,4-dimethylpiperazinium 801 
MRM: Multiple reaction monitoring 802 
OFN: Oxygen-free nitrogen 803 
PPZ: 1-(2,4-dinitro-5-fluorophenyl)-4-methylpiperazine 804 
PR: Progesterone receptor 805 
UHPLC: Ultra-high-performance liquid chromatography 806 
WC: Waist circumference 807 
  808 
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TABLES 809 
Table 1: Sequence primers and gene description 810 
Gene Symbol Description GenBank 
size 
(pb) 
Primer sequence  5'→3' 
S/AS 
HSD11B1 
Homo sapiens hydroxysteroid 11-beta 







Homo sapiens cytochrome P450, family 
19, subfamily A, polypeptide 1 






Homo sapien hydroxysteroid (17-beta) 






Homo sapiens hydroxysteroid (17-beta) 






Homo sapiens estrogen receptor 1 






Homo sapiens estrogen receptor 2 






Homo sapiens ATP synthase,  H+ 
transporting, mitochondrial F1 complex, 






Homo sapiens hypoxanthine 













  812 
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Table 2: Clinical characteristics of the women with breast cancer and 813 
control women 814 











Age (years) 55.0 (50.1-62.9) 53.7 (44.9-57.5) 55.9 (53.2-63.2) 
Menopausal status    
Premenopausal n (%) 8 (35) 2 (33) 6 (35) 
Postmenopausal n (%) 15 (65) 4 (67) 11 (65) 
Anthropometrics    
BMI (kg/m2) 25.6 (24.3-28.2) 27.1 (24.3-29.4) 25.4 (24.5-26.8) 
WC (cm) − − 94 (86-99) 
Breast adipocyte mean diameter 
(µm) 
75.5 (67.3-87.5)a 87.9 (86.2-89.5) 74.1 (66.1-80.3)b 
Hormonal derivatives    
Current oral contraceptive use (yes) 
n (% of premenopausal) 
6 (75) 1 (50) 5 (83) 
Current HRT use (yes) 
n (% of postmenopausal) 
5 (33) 2 (50) 3 (27) 
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Lesion    
unilateral 5 (83.33) 10 (90.91) 15 (88.24) 
bilateral 1 (16.67) 1 (9.09) 2 (11.76) 
Histology    
Ductal 6 (100.00) 8 (72.73) 14 (82.35) 
Othersa 0 (0.00) 3 (27.27) 3 (17.65) 
Receptor status    
ER+/PR+ 5 (83.33) 8 (72.73) 13 (76.47) 
TNM status    
0 0 (0.00) 3 (27.27) 3 (17.65) 
1 2 (33.33) 4 (36.36) 6 (35.29) 
2 4 (66.67) 4 (36.36) 8 (47.06) 
aincludes lobular, mucinous and metaplastic carcinomas. Key: ER, estrogen receptor; PR, progesterone 817 
receptor.  818 
Laforest et al. 2019, page 40 




















Estrone (pmol/kg) 3744 (2847-9899) 7855 (3062-18998) 3744 (2514-7415) 0.1611 
Estradiol (pmol/kg) 2320 (1537-4160) 2747 (1796-2937) 2306 (1537-4160) 0.4211 
Ratio 
Cortisol/Cortisone 
4.13 (2.47-15.09) 42.28 (15.09-56.09) 3.35 (2.26-5.54) <0.0001 
Ratio 
Estradiol/Estrone 
0.46 (0.32-0.66) 0.54 (0.15-0.65) 0.44 (0.33-0.63) 0.6059 
*Student t-test p-values calculated with log-transformed variables. #Satterthwaite adjusted p-value 821 
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Table 5: Clinical characteristics of the women with ER-PR- breast cancer 823 
and control women 824 








Age (years) 53.7 (44.9-57.5) 54.9 (53.6-60.29) 
BMI (kg/m2) 27.1 (24.3-29.4) 26.0 (25.5-26.6) 
Premenopausal n (%) 2 (33) 1 (25) 
Postmenopausal n (%) 4 (67) 3 (75) 



